Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells

Laura J. Vella, Anupama Pasam, Nektaria Dimopoulos, Miles Andrews, Ashley Knights, Anne-Laure Puaux, Jamila Louahed, Weisan Chen, Katherine Woods and Jonathan S. Cebon
Laura J. Vella
1Cancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Heidelberg; 2School of Molecular Science, La Trobe University, Bundoora, Victoria, Australia; and 3GlaxoSmithKline Vaccines, Rixensart, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anupama Pasam
1Cancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Heidelberg; 2School of Molecular Science, La Trobe University, Bundoora, Victoria, Australia; and 3GlaxoSmithKline Vaccines, Rixensart, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nektaria Dimopoulos
1Cancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Heidelberg; 2School of Molecular Science, La Trobe University, Bundoora, Victoria, Australia; and 3GlaxoSmithKline Vaccines, Rixensart, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miles Andrews
1Cancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Heidelberg; 2School of Molecular Science, La Trobe University, Bundoora, Victoria, Australia; and 3GlaxoSmithKline Vaccines, Rixensart, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashley Knights
1Cancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Heidelberg; 2School of Molecular Science, La Trobe University, Bundoora, Victoria, Australia; and 3GlaxoSmithKline Vaccines, Rixensart, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne-Laure Puaux
1Cancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Heidelberg; 2School of Molecular Science, La Trobe University, Bundoora, Victoria, Australia; and 3GlaxoSmithKline Vaccines, Rixensart, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jamila Louahed
1Cancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Heidelberg; 2School of Molecular Science, La Trobe University, Bundoora, Victoria, Australia; and 3GlaxoSmithKline Vaccines, Rixensart, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weisan Chen
1Cancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Heidelberg; 2School of Molecular Science, La Trobe University, Bundoora, Victoria, Australia; and 3GlaxoSmithKline Vaccines, Rixensart, Belgium
1Cancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Heidelberg; 2School of Molecular Science, La Trobe University, Bundoora, Victoria, Australia; and 3GlaxoSmithKline Vaccines, Rixensart, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine Woods
1Cancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Heidelberg; 2School of Molecular Science, La Trobe University, Bundoora, Victoria, Australia; and 3GlaxoSmithKline Vaccines, Rixensart, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan S. Cebon
1Cancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Heidelberg; 2School of Molecular Science, La Trobe University, Bundoora, Victoria, Australia; and 3GlaxoSmithKline Vaccines, Rixensart, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6066.CIR-13-0181 Published April 2014
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Trametinib and combination decrease T-lymphocyte proliferation. The proliferation index (A and C) and viability (B and D) of CD3/CD28-activated CFSE-labeled CD4+ (A and C) and CD8+ (B and D) T cells treated for 5 days with dabrafenib or trametinib, alone or in combination. Each point represents the mean value from the results obtained with 4 healthy donors; error bars show the SEM. One-way ANOVA with a Dunnett post test against the untreated control was performed. *, P < 0.05; **, P < 0.01; ***, P < 0.001. The proliferation index was determined using the proliferation tool in the FlowJo software package. This value represents the average number of cell divisions that the cells underwent by considering only the fraction of proliferated cells. Dabrafenib, BRAFi; trametinib, MEKi. Representative flow cytometry data are presented in Supplementary Fig. S1.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Trametinib and combination decrease T-lymphocyte cytokine production. The percentage of IFN-γ (A) and IL-17 (B) positive CD4+ T cells, and IFN-γ (C) and TNF-α (D) positive CD8+ T cells following treatment with dabrafenib or trametinib, alone or in combination was assessed by ICS flow cytometry 24 hours after activation by PMA–ionomycin. The percentage of cytokine-producing cells is shown as a fraction of total CD3+CD4+ (A and B) or CD3+CD8+ (C and D) T cells. Mean values with SEM from 8 healthy donors are shown. One-way ANOVA with a Dunnett post test against the untreated control was performed. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Dabrafenib, BRAFi; trametinib, MEKi. Representative flow cytometry data are presented in Supplementary Fig. S2.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Trametinib and combination affect the proliferation of antigen-specific T lymphocytes. The effect of kinase inhibition on in vitro stimulation of peptide-specific CD8+T cells was assessed 10 days after stimulation of PBMCs with an HLA-A2–restricted synthetic peptide for EBV BMLF1 (280–288). The percentage of dead PBMCs (A) and percentage of CD3+CD8+ T cells in the viable PBMC population (B) following 10 days of kinase inhibition are shown. Specific T cells were detected by ICS using fluorescently tagged antibodies to TNF-α (C) and IFN-γ (D). The percentage of TNF-α or IFN-γ producing CD8+ T cells was determined by fluorescence-activated cell sorting analysis. Each point represents a mean value from multiple stimulations performed with samples from 6 healthy donors and the mean with SEM is indicated. Two-way ANOVA with a Bonferroni post test against the DMSO control was performed. *, P < 0.05; ***, P < 0.001. Dabrafenib, BRAFi; trametinib, MEKi. Representative flow cytometry data are presented in Supplementary Fig. S3.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Dabrafenib and trametinib in combination inhibit cross-presentation in vitro. Immature HLA-specific moDCs were treated for 18 hours with dabrafenib or trametinib, alone or in combination in the presence or absence of NY-ESO-1 peptide (positive control) and NY-ESO-1 protein and His-tag antibody. After 24 hours, an NY-ESO-1–specific, HLA-restricted CD8+ T-cell clone was added to the treated and peptide-pulsed moDC to assess cross-presentation of NY-ESO-1 epitope in a standard recognition assay (no drug was present during the 4-hour APC–T-cell coculture) measuring specific cytokine secretion by the T-cell clone upon activation. Non–antigen-pulsed moDCs were used as the negative control (not shown). A, the capacity of HLA-A2+ moDCs to cross-present NY-ESO-1–derived epitope (157–165) to the NY-ESO-1–specific CD8+ T-cell clone (157-165/HLA-A2) in vitro. B, positive control; following drug treatment, moDCs were pulsed for 1 hour with the synthetic peptide for which the T-cell clone was specific. C, NY-ESO-1 protein with anti-IgG1 isotype control. Mean values with SEM from 4 healthy donors are shown. One-way ANOVA with a Dunnett post test against the control was performed; *, P < 0.05; **, P < 0.01; ***, P < 0.001. Dabrafenib, BRAFi; trametinib, MEKi.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Trametinib and combination promote moDC maturation and decrease moDC viability. A, moDCs were incubated with the indicated concentrations of individual inhibitors or combinations, for 24 hours, in the presence of LPS. Cells were stained with fluorescently labeled live/dead stain, CD86, CD83, or anti–HLA-DR antibodies. MFI of bound antibody was determined by flow cytometry. Representative single-parameter histograms show the expression of CD80, CD83, and CD86 by MoDCs (gray) after the addition of LPS (dotted black line gray) or 30 nmol/L trametinib plus LPS (solid black line). B, moDCs were incubated with the indicated concentrations of individual inhibitors or combinations, for 24 or 48 hours. The toxicity exerted by the individual and combined inhibitors was assessed using a fluorescent live/dead dye. Mean values with SEM from 4 healthy donors are shown. One-way ANOVA with a Dunnett post test against the control was performed. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Dabrafenib, BRAFi; trametinib, MEKi.

Additional Files

  • Figures
  • Supplementary Data

    Files in this Data Supplement:

    • Supplementary Figure Legends - PDF file - 79K
    • Supplementary Figures 1 - 3 - PDF file - 376K, Supplementary Figure 1. Representative flow cytometry data of T-cell proliferation. Supplementary Figure 2. Gating strategy for T-lymphocyte cytokine production. Supplementary Figure 3. Gating strategy for antigen specific T-lymphocytes.
PreviousNext
Back to top
Cancer Immunology Research: 2 (4)
April 2014
Volume 2, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells
Laura J. Vella, Anupama Pasam, Nektaria Dimopoulos, Miles Andrews, Ashley Knights, Anne-Laure Puaux, Jamila Louahed, Weisan Chen, Katherine Woods and Jonathan S. Cebon
Cancer Immunol Res April 1 2014 (2) (4) 351-360; DOI: 10.1158/2326-6066.CIR-13-0181

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells
Laura J. Vella, Anupama Pasam, Nektaria Dimopoulos, Miles Andrews, Ashley Knights, Anne-Laure Puaux, Jamila Louahed, Weisan Chen, Katherine Woods and Jonathan S. Cebon
Cancer Immunol Res April 1 2014 (2) (4) 351-360; DOI: 10.1158/2326-6066.CIR-13-0181
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Myeloid-Targeted CXCR2 Deletion Improves Antitumor Immunity
  • Metabolic Screening of CD8+ T Cells
  • Nutlin-3a: An Immune-Checkpoint Activator for NK Cells in Neuroblastoma
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement